Dr. Karl Mulligan has over 20 years of experience in oncology research, diagnostics, and life sciences commercialization. He is the Co-Founder and Chief Operating Officer of CV6 Therapeutics (NI) Ltd., where he has led operations since the company’s inception in 2014, overseeing the strategic development and advancement of novel therapeutics in oncology and inflammatory diseases.

Prior to founding CV6, Karl served as Global Vice President of Almac Diagnostics, where he successfully established and led R&D, clinical, and operational teams across the UK and USA. His multidisciplinary teams supported major biotech and pharmaceutical partners with biomarker discovery, companion diagnostic development, and clinical testing programs.

Karl also serves as an Entrepreneur in Residence at Catalyst Inc. (formerly the Northern Ireland Science Park), advising early-stage life science companies on product development and commercialization strategies.

He holds a BSc (Hons) from the University of Liverpool and earned his PhD in molecular oncology from Queen’s University Belfast. Karl is a board member of CV6 Therapeutics (NI) Ltd.